Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 324

1.

An effective mouse model for adoptive cancer immunotherapy targeting neoantigens.

Hanada KI, Yu Z, Chappell GR, Park AS, Restifo NP.

JCI Insight. 2019 May 16;4(10). pii: 124405. doi: 10.1172/jci.insight.124405. eCollection 2019 May 16.

2.

T cell stemness and dysfunction in tumors are triggered by a common mechanism.

Vodnala SK, Eil R, Kishton RJ, Sukumar M, Yamamoto TN, Ha NH, Lee PH, Shin M, Patel SJ, Yu Z, Palmer DC, Kruhlak MJ, Liu X, Locasale JW, Huang J, Roychoudhuri R, Finkel T, Klebanoff CA, Restifo NP.

Science. 2019 Mar 29;363(6434). pii: eaau0135. doi: 10.1126/science.aau0135.

PMID:
30923193
3.

Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.

Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, Fine HA, Rosenberg SA.

J Immunother. 2019 May;42(4):126-135. doi: 10.1097/CJI.0000000000000260.

PMID:
30882547
4.

The transcription factor c-Myb regulates CD8+ T cell stemness and antitumor immunity.

Gautam S, Fioravanti J, Zhu W, Le Gall JB, Brohawn P, Lacey NE, Hu J, Hocker JD, Hawk NV, Kapoor V, Telford WG, Gurusamy D, Yu Z, Bhandoola A, Xue HH, Roychoudhuri R, Higgs BW, Restifo NP, Bender TP, Ji Y, Gattinoni L.

Nat Immunol. 2019 Mar;20(3):337-349. doi: 10.1038/s41590-018-0311-z. Epub 2019 Feb 18.

PMID:
30778251
5.

Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers.

Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, Gartner JJ, Hill V, Yu Z, Restifo NP, Sachs A, Tran E, Lo W, Somerville RP, Rosenberg SA, Deniger DC.

J Clin Invest. 2019 Mar 1;129(3):1109-1114. doi: 10.1172/JCI123791. Epub 2019 Feb 4. No abstract available.

6.

Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance.

Wei J, Kishton RJ, Angel M, Conn CS, Dalla-Venezia N, Marcel V, Vincent A, Catez F, Ferré S, Ayadi L, Marchand V, Dersh D, Gibbs JS, Ivanov IP, Fridlyand N, Couté Y, Diaz JJ, Qian SB, Staudt LM, Restifo NP, Yewdell JW.

Mol Cell. 2019 Mar 21;73(6):1162-1173.e5. doi: 10.1016/j.molcel.2018.12.020. Epub 2019 Jan 31.

PMID:
30712990
7.

T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.

Yamamoto TN, Lee PH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, Eidizadeh A, Eil R, Fioravanti J, Gattinoni L, Kochenderfer JN, Fry TJ, Aksoy BA, Hammerbacher JE, Cruz AC, Siegel RM, Restifo NP, Klebanoff CA.

J Clin Invest. 2019 Feb 25;129(4):1551-1565. doi: 10.1172/JCI121491. eCollection 2019 Feb 25.

8.

Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism.

Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, Maseda D, Liberti MV, Paz K, Kishton RJ, Johnson ME, de Cubas AA, Wu P, Li G, Zhang Y, Newcomb DC, Wells AD, Restifo NP, Rathmell WK, Locasale JW, Davila ML, Blazar BR, Rathmell JC.

Cell. 2018 Dec 13;175(7):1780-1795.e19. doi: 10.1016/j.cell.2018.10.001. Epub 2018 Nov 1.

PMID:
30392958
9.

Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.

Jin BY, Campbell TE, Draper LM, Stevanović S, Weissbrich B, Yu Z, Restifo NP, Rosenberg SA, Trimble CL, Hinrichs CS.

JCI Insight. 2018 Apr 19;3(8). pii: 99488. doi: 10.1172/jci.insight.99488. eCollection 2018 Apr 19.

10.

The Cish SH2 domain is essential for PLC-γ1 regulation in TCR stimulated CD8+ T cells.

Guittard G, Dios-Esponera A, Palmer DC, Akpan I, Barr VA, Manna A, Restifo NP, Samelson LE.

Sci Rep. 2018 Mar 28;8(1):5336. doi: 10.1038/s41598-018-23549-2.

11.

Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System.

Vizcardo R, Klemen ND, Islam SMR, Gurusamy D, Tamaoki N, Yamada D, Koseki H, Kidder BL, Yu Z, Jia L, Henning AN, Good ML, Bosch-Marce M, Maeda T, Liu C, Abdullaev Z, Pack S, Palmer DC, Stroncek DF, Ito F, Flomerfelt FA, Kruhlak MJ, Restifo NP.

Cell Rep. 2018 Mar 20;22(12):3175-3190. doi: 10.1016/j.celrep.2018.02.087.

12.

A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed.

Lin CC, Kurashige M, Liu Y, Terabayashi T, Ishimoto Y, Wang T, Choudhary V, Hobbs R, Liu LK, Lee PH, Outeda P, Zhou F, Restifo NP, Watnick T, Kawano H, Horie S, Prinz W, Xu H, Menezes LF, Germino GG.

Sci Rep. 2018 Feb 9;8(1):2743. doi: 10.1038/s41598-018-20856-6.

13.

Epigenetic control of CD8+ T cell differentiation.

Henning AN, Roychoudhuri R, Restifo NP.

Nat Rev Immunol. 2018 May;18(5):340-356. doi: 10.1038/nri.2017.146. Epub 2018 Jan 30. Review.

14.

Silencing stemness in T cell differentiation.

Henning AN, Klebanoff CA, Restifo NP.

Science. 2018 Jan 12;359(6372):163-164. doi: 10.1126/science.aar5541. No abstract available.

15.

Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.

Klebanoff CA, Crompton JG, Leonardi AJ, Yamamoto TN, Chandran SS, Eil RL, Sukumar M, Vodnala SK, Hu J, Ji Y, Clever D, Black MA, Gurusamy D, Kruhlak MJ, Jin P, Stroncek DF, Gattinoni L, Feldman SA, Restifo NP.

JCI Insight. 2017 Dec 7;2(23). pii: 95103. doi: 10.1172/jci.insight.95103.

16.

ASXL3 Is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer.

Shukla V, Rao M, Zhang H, Beers J, Wangsa D, Wangsa D, Buishand FO, Wang Y, Yu Z, Stevenson HS, Reardon ES, McLoughlin KC, Kaufman AS, Payabyab EC, Hong JA, Zhang M, Davis S, Edelman D, Chen G, Miettinen MM, Restifo NP, Ried T, Meltzer PA, Schrump DS.

Cancer Res. 2017 Nov 15;77(22):6267-6281. doi: 10.1158/0008-5472.CAN-17-0570. Epub 2017 Sep 21.

17.

Identification of essential genes for cancer immunotherapy.

Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP, Day CP, Robbins P, Feldman S, Merlino G, Zhang F, Restifo NP.

Nature. 2017 Aug 31;548(7669):537-542. doi: 10.1038/nature23477. Epub 2017 Aug 7.

18.

Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy.

Kishton RJ, Sukumar M, Restifo NP.

Cell Metab. 2017 Jul 5;26(1):94-109. doi: 10.1016/j.cmet.2017.06.016. Review.

19.

Novel "Elements" of Immune Suppression within the Tumor Microenvironment.

Gurusamy D, Clever D, Eil R, Restifo NP.

Cancer Immunol Res. 2017 Jun;5(6):426-433. doi: 10.1158/2326-6066.CIR-17-0117. Review.

20.

BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency.

Afzali B, Grönholm J, Vandrovcova J, O'Brien C, Sun HW, Vanderleyden I, Davis FP, Khoder A, Zhang Y, Hegazy AN, Villarino AV, Palmer IW, Kaufman J, Watts NR, Kazemian M, Kamenyeva O, Keith J, Sayed A, Kasperaviciute D, Mueller M, Hughes JD, Fuss IJ, Sadiyah MF, Montgomery-Recht K, McElwee J, Restifo NP, Strober W, Linterman MA, Wingfield PT, Uhlig HH, Roychoudhuri R, Aitman TJ, Kelleher P, Lenardo MJ, O'Shea JJ, Cooper N, Laurence ADJ.

Nat Immunol. 2017 Jul;18(7):813-823. doi: 10.1038/ni.3753. Epub 2017 May 22.

Supplemental Content

Loading ...
Support Center